Sexton Biotechnologies

Sexton Biotechnologies develops specialized cell and gene therapy tools, focusing on biopreservation and advanced media solutions to enhance the viability and performance of biologics in regenerative medicine. Founded in 2019 and headquartered in Indianapolis, US, Sexton Biotechnologies creates solutions for cryopreservation and storage of biological materials. Co-founded by Jay Gilliland, Lindsay Newton, and Vicky Tran, the company was acquired by BioLife Solutions in a TRADE SALE for USD 24. 00 mn on August 9, 2021.

This acquisition aims to enhance BioLife's portfolio of cell and gene therapy tools. Sexton Biotechnologies specializes in biopreservation and cell processing solutions tailored for regenerative medicine and cell and gene therapy applications. Their key products include CryoStor® and HypoThermosol®, which are advanced media for cryopreservation and hypothermic storage of biologics. They also provide pathogen-reduced human platelet lysates (hPL) such as Stemulate™, nLiven PR™, and T-Liven PR™ to improve cell performance in clinical settings, utilized by over 500 clinical applications globally.

Sexton Biotechnologies generates revenue through the sale of proprietary biopreservation products and processing media, primarily through a direct B2B model. Their transactions involve bulk orders from clinical research organizations and pharmaceutical companies that seek reliable solutions for cell storage and processing, with pricing based on product configurations and volumes. The acquisition by BioLife Solutions will support the expansion of Sexton Biotechnologies’ product offerings in cell and gene therapy tools. The company aims to introduce new products and expand into additional markets in the coming years, leveraging the USD 24.

00 mn investment to enhance research and development initiatives. The strategic focus includes increasing their presence in North America, Europe, and Asia to meet the growing demands of the regenerative medicine sector.